Bionano Genomics (NASDAQ:BNGO) Issues Earnings Results

Bionano Genomics (NASDAQ:BNGO) released its quarterly earnings data on Monday. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.03, FiscalAI reports. Bionano Genomics had a negative return on equity of 71.38% and a negative net margin of 109.94%.The firm had revenue of ($6.67) million during the quarter, compared to the consensus estimate of $7.55 million.

Here are the key takeaways from Bionano Genomics’ conference call:

• Q2 revenue rose 21% year over year to $8.2 million, exceeding guidance, while consumable revenue increased 30% and flow-cell sales reached a record 9,219 units, up 27%. Growth was driven primarily by higher utilization among existing clinical customers.
• Bionano raised the low end of its 2026 revenue outlook to $31 million–$33 million and initiated Q3 guidance of $8.2 million–$8.6 million. Management cited accelerating clinical adoption, reimbursement progress, and international growth as key drivers.
• Demand for nanochannel array flow cells continues to exceed manufacturing capacity, with the company carrying a backlog. Supply constraints led management to leave the high end of full-year guidance unchanged while it works to expand production by mid-to-late Q4.
• Adjusted gross margin reached a quarterly record of 53%, up from 52% a year ago, while operating expenses declined slightly. The company also fully retired its senior secured convertible debt, although ending cash and available securities totaled $10.4 million with runway expected only into at least Q1 2027.
• Bionano reported expanding clinical evidence for optical genome mapping, including a 91-case T-ALL study in which OGM detected abnormalities in 97.8% of cases versus 55% for conventional karyotyping. The company is also targeting a Q4 2026 launch of an Ionic workflow that interfaces directly with OGM and long-read sequencing sample preparation.

Bionano Genomics Stock Performance

Shares of BNGO opened at $1.16 on Tuesday. The company has a current ratio of 1.84, a quick ratio of 1.59 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $13.32 million, a price-to-earnings ratio of -0.27 and a beta of 1.63. The stock has a 50 day moving average of $1.15 and a 200 day moving average of $1.19. Bionano Genomics has a 12 month low of $1.00 and a 12 month high of $5.50.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Carret Asset Management LLC lifted its position in shares of Bionano Genomics by 76.4% during the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after buying an additional 19,100 shares during the last quarter. DRW Securities LLC purchased a new stake in Bionano Genomics in the 4th quarter worth about $258,000. Geode Capital Management LLC raised its stake in Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after acquiring an additional 39,928 shares during the period. Renaissance Technologies LLC bought a new stake in Bionano Genomics in the 4th quarter valued at about $57,000. Finally, Jane Street Group LLC purchased a new stake in Bionano Genomics during the fourth quarter valued at about $34,000. Institutional investors own 11.35% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright reduced their price target on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Wall Street Zen upgraded shares of Bionano Genomics to a “hold” rating in a report on Saturday, June 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bionano Genomics in a research note on Wednesday, July 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $6.00.

Bionano Genomics Company Profile

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.